InspireMD Moves Third-Quarter Earnings Call to 4:30 p.m.
Key Facts
InspireMD said its 2026 third-quarter earnings call will be held on November 12 at 4:30 p.m. Eastern Time, after U.S. financial markets close, instead of the previously scheduled 8:30 a.m. The company said the rescheduling would allow management to provide investors with a more comprehensive update alongside the results. The new time puts the call after the U.S. trading session ends that day. It also links the results presentation directly to a discussion of the company’s latest developments and business activities. Available information did not confirm a new FDA approval for use of the CGuard Prime system in TCAR procedures.
In its statement on the schedule change, the company said the revised time “will allow management to provide a more comprehensive update on the company’s recent developments and business activities alongside its third-quarter financial results.” The clarification indicates that the call’s agenda combines a financial performance presentation with a review of business developments. The company had previously announced an 8:30 a.m. Eastern Time slot, before moving it to 4:30 p.m. The revised time is on November 12, 2026, after the U.S. market closes. Available information did not include third-quarter results figures or financial forecasts for comparison.
The confirmed regulatory context for the CGuard Prime system dates to June 23, 2025, when the FDA approved the original system. Its published indication was to improve carotid artery lumen diameter in certain patients at high risk for endarterectomy. The minimum stenosis was 50% for patients with neurological symptoms and 80% for those without neurological symptoms. The indication also specified a reference vessel diameter of 6.4 to 9.0 mm at the target lesion. These criteria describe the original indication published in 2025 and do not establish a separate approval for TCAR procedures.
In results from the CGUARDIANS II trial published in June 2026, InspireMD said acute device success was achieved in 100% of participants, or 50 of 50 patients. It added that the trial recorded no deaths, strokes or myocardial infarctions within 30 days. The company published the results on June 11, specifying a 30-day observation period. The figures provide clinical context on the 80 cm CGuard Prime version used in the trial for TCAR procedures. These results do not in themselves announce a new regulatory decision.
The company said on September 21, 2026, that it still expected an FDA decision on the 80 cm CGuard Prime during the fourth quarter of the year. In the same announcement, it said it had amended the terms of certain warrants to align with the decision timing then expected. Its chief executive also estimated that more than 35,000 TCAR procedures are performed annually in the United States, saying that adding this use could double the system’s U.S. addressable market. The company presented the figure as an estimate of annual procedure volume, not as a figure for confirmed sales or additional procedures. The decision timing it announced in September remained an expectation for the fourth quarter.
On financing, InspireMD said in September that amendments to existing warrants could generate potential gross proceeds of up to $11 million. It said full exercise of the warrants, together with existing cash balances, was expected to provide resources to fund the launch of the 80 cm version after approval. The $11 million figure remains potential proceeds tied to warrant exercise, according to the company’s wording. The company linked launch funding to approval of the version, while available information did not specify a separate launch date. At the November 11, 2026, close, NSPR shares stood at $0.8, according to EL7 data.